Company intelligence / Profile preview

Bolder Insights

Boulder, Colorado, United Statesboldergroup.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

The company has demonstrated positive preclinical data on several candidates including long-lasting analogs of cytokines and growth factors. Notably, its IL‑11 analog BBT‑059 has received continued NIH/NIAID funding for development as a medical countermeasure against acute radiation syndrome; IND-enabling studies are ongoing with plans to advance into human trials.

Therapeutic areas: Infectious DiseasesNeurologyHematology
Modalities: Recombinant proteinInterferonsAntibody-drug conjugate (ADC)Colony-stimulating factorsInterleukinsSmall molecule
Industry: Biotech

Partnerships

Collaborations with NIH/NIAID on ARS program developmentstrategic alliances mentioned but not specified by name

Beyond the preview

Go deeper on Bolder Insights.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bolder Insights.

Explore the full profile